MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia

Article English OPEN
Dong Xu; Alexandrea G. Ham; Rickey D. Tivis; Matthew L. Caylor; Aoxiang Tao; Steve T. Flynn; Peter J. Economen; Hung K. Dang; Royal W. Johnson; Vaughn L. Culbertson;
(2017)
  • Publisher: Elsevier
  • Journal: EBioMedicine,volume 26,pages132-137 (issn: 2352-3964, eissn: 2352-3964)
  • Related identifiers: doi: 10.1016/j.ebiom.2017.11.015, pmc: PMC5832625
  • Subject: Drug-drug interactions | R | Drug repurposing | Metoclopramide | Drug safety | Combination therapy | Medicine | Research Paper | Tardive dyskinesia

In 2009 the U.S. Food and Drug Administration (FDA) placed a black box warning on metoclopramide (MCP) due to the increased risks and prevalence of tardive dyskinesia (TD). In this study, we developed a multi-step biomedical informatics screening (MSBIS) approach levera... View more
Share - Bookmark